Company Overview: What Fisher and Paykel Healthcare Does

Fisher and Paykel Healthcare was established as an offshoot of the Fisher and Paykel appliance business and has since grown into an entirely separate global enterprise. Research, development, and manufacturing operations are primarily based in Auckland and in Monterrey, Mexico, with a global sales force and distribution network serving hospitals and healthcare providers in over 120 countries.

The Hospital division is where much of the company's growth story has played out. FPH's investment in nasal high-flow therapy — delivering humidified, high-velocity oxygen through the Optiflow system — transformed a niche intensive care technique into a standard of care in respiratory support across many hospital settings globally. The clinical evidence base supporting high-flow therapy has grown substantially, driving both new patient populations and expanded usage within existing accounts. The consumable nature of respiratory circuits and disposable components used with these systems provides a significant recurring revenue stream alongside the capital equipment business.

Homecare: The Sleep Apnea Market

The Homecare division addresses the obstructive sleep apnea market, where patients are prescribed CPAP therapy to maintain airway function during sleep. FPH designs and manufactures a range of masks — including nasal, full-face, and pillow-style designs — along with CPAP devices and accessories. Sleep apnea is a large and growing market, driven by rising global obesity rates, ageing populations, and increased clinical awareness of the condition's links to cardiovascular disease and other serious health outcomes. FPH competes alongside a small number of global specialised medical device companies in this space and has maintained a meaningful competitive presence through sustained product innovation and strong clinical relationships.

Why Fisher and Paykel Healthcare (FPH) Stock Is Attracting Attention

FPH has fallen, generating significant commentary among investors who follow NZX healthcare stocks and global health-tech equities. Valuation is at the heart of the discussion. FPH has historically traded at a substantial premium justified by high and sustained revenue growth, excellent operating margins, a strong balance sheet, and a consistent track record of product innovation driving market share gains.

When a premium-growth stock falls, investors ask whether the valuation premium is being maintained, compressed, or eliminated. Any signal suggesting revenue growth may moderate — from a tougher competitive environment, slower hospital penetration of new product categories, or macro pressures on healthcare spending in key markets — tends to generate a more significant share price reaction for a high-multiple stock than for an average-valued company.

Currency is central to the FPH investment narrative. The company earns most of its revenues in USD and EUR but reports in NZD. When the NZD strengthens against these currencies, the NZD translation of offshore earnings is reduced, creating a headwind to reported financial growth even when underlying business performance is strong. The NZD-USD and NZD-EUR exchange rates are among the most-watched inputs for FPH shareholders and analysts tracking the stock.

The broader reassessment of health-tech and medical device valuations globally adds a further dimension. After a period in which healthcare stocks attracted elevated multiples on the perceived defensive quality of their revenues, a normalisation has occurred in parts of the sector. FPH, as one of the most highly valued healthcare stocks on the NZX, is not immune to such recalibrations when investor risk appetite shifts or interest rate environments change.

Sector and Market Backdrop

The global medical device sector benefits from long-term demographic tailwinds — ageing populations in developed markets driving higher rates of chronic disease and hospitalisation — while also facing regulatory complexity, competitive product development cycles, and reimbursement pressures from healthcare systems under fiscal strain. Respiratory care is an area of particular structural growth, with advances in the clinical understanding of respiratory support expanding the eligible patient population for the devices and therapies FPH produces. This structural tailwind is one of the reasons FPH commands investor attention across market cycles.

New Zealand equities investors regard FPH as the country's pre-eminent healthcare stock and one of the highest-quality businesses in the NZX50. Its weighting in the benchmark index means institutional funds tracking New Zealand equities must hold significant positions in the company. The competitive landscape in respiratory care and sleep medicine has evolved, with a small number of highly specialised global medical device companies active in FPH's core markets. Maintaining and extending market positions requires sustained investment in clinical research, product development, and commercial operations globally.

Key Opportunities

The most significant long-term growth opportunity for FPH remains continued penetration of nasal high-flow therapy in hospital settings globally. While adoption in major developed markets has grown substantially, significant opportunities remain in emerging market hospitals, in new clinical indications for high-flow therapy, and in converting patients from older respiratory support modalities. Each of these represents a pathway to sustained revenue growth supported by expanding clinical evidence.

In the Homecare division, the sleep apnea market continues to grow as awareness of the condition increases among patients and healthcare providers. Product innovation in mask design and the integration of digital connectivity in CPAP devices represent sources of competitive differentiation and market share opportunity. The company's manufacturing investment — including its Monterrey facilities — provides optionality to scale production as demand grows without proportionally increasing cost per unit.

Key Risks

Valuation risk is the most prominent concern for existing FPH shareholders. A premium multiple implies elevated expectations for future growth, and any disappointment — from slower hospital penetration, competitive product launches, currency headwinds, or softer healthcare spending — could result in multiple compression that compounds any earnings-level miss. Premium stocks can see significant price corrections even when underlying business performance is merely good rather than exceptional.

Currency risk is structural and ongoing. FPH's reliance on USD and EUR revenues means that a sustained NZD appreciation reduces reported earnings in NZD terms without any change in operational performance. Competitive risk is real — major global medical device companies with significant resources compete in respiratory care and sleep medicine — and reimbursement changes in major healthcare markets could affect the addressable market for certain product categories. Regulatory requirements across more than 120 country markets add further operational complexity that is intrinsic to the business model.

Investor Takeaway

Fisher and Paykel Healthcare is arguably New Zealand's most internationally recognised listed company — a global medical device leader with products in hospitals and homes across more than 120 countries. The recent fall has brought the stock to the attention of investors weighing whether the valuation recalibration has created an entry point into one of the NZX's highest-quality businesses, or whether further downside is possible before the premium valuation is fully justified by the near-term earnings outlook.

Investors who take a long-term view on the structural growth of respiratory care and sleep medicine — and who are comfortable with the currency and valuation risks inherent in an export-focused health-tech company at premium multiples — may find FPH worth watching closely. The company's track record of innovation and commercial execution is one of the most compelling in the New Zealand equities universe. FPH could stay on the watchlists of both domestic and international investors with an interest in NZX healthcare stocks and global health-tech companies as market conditions continue to evolve.

Disclaimer

Disclaimer: This article is for general information only and does not constitute financial advice. Investors should conduct their own research or consult a licensed financial adviser before making investment decisions.